Notitia Biotechnologies news
After months of preparation, Notitia Biotechnologies Company (Notitia) announced that its COVID-19 Phase 2 study (COVGUT20) for NBT-NM108 has been given support by the Food and Drug Administration (FDA) to expand its study population to all symptomatic COVID-19 patients.
"Previously, our trial focused on COVID-19 patients with type 2 diabetes and prediabetes. Now with this timely expansion to our study population, we can help more people and test NBT- NM108’s efficacy not jus
A Rutgers scientist has invented an early treatment for COVID-19 to prevent severe complications and hospitalizations in patients with prediabetes and diabetes by increasing beneficial bacteria in the gut and reducing organisms that cause coronavirus.
The treatment – created by researcher Liping Zhao – was given the Investigational New Drug status by the Food and Drug Administration and will start Phase 2a trial Feb. 8. While the treatment, NBT-NM108, does not targe
Notitia Biotechnologies Company has received the Investigational New Drug (IND) approval from the FDA for NBT-NM108, a proprietary formula designed to support the Foundation Guild bacteria in the patient`s gut microbiome. The FDA has allowed Notitia to test the drug as a treatment for COVID-19 in patients with type 2 diabetes and prediabetes. Notitia has secured funding for a Phase 2a randomized, controlled clinical trial, and the study will be performed in the Tampa Florida area. Enro
Notitia Biotechnologies Company has developed a ground-breaking live biotherapeutic product (LBP) for patients with early-stage and end-stage diabetic kidney disease (DKD) patients. The drug, NBT-BM306, combines the purified Foundation Guild bacteria and the tailored microbiome nutrition to support their growth in one convenient format.
Notitia is preparing the Investigational New Drug (IND) application to the FDA to start a Phase 1/2 combined clinical trial in Q1 2021.